Design of iron chelators with therapeutic application
The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Iron is essential for the proper functioning of all living cells, however it is toxic when present in excess. Thus, using iron chelators as therapeutic agents, namely chelation therapy, has received increasing attention. The objective of this review is to discuss the factors which should be considered when designing clinically useful iron chelators, to present the application of iron chelators in the treatment of iron overload associated with β-thalassaemia major and sickle cell anaemia, and to highlight the potential applications in the treatment of neurodegenerative disorders and microbial infection. This article reviews recent knowledge centred on these themes and indicates the growing importance of the concept of iron chelation in medicine.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An effective iron chelator must be nontoxic, must have higher affinity for ferric iron than bacterial siderophores and must not be recognized by microbial siderophore transporters94.”
From Iron homeostasis in host defence and inflammation (2015) · cites this paper as [94]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Chemistry and biology of siderophores
Hider, R. C., & Kong, X. (2010) · Natural Product Reports · doi:10.1039/b906679a · Cited by 1,722
Self-citationRae, T. D., Schmidt, P. J., Pufahl, R. A., Culotta, V. C., & V. O'Halloran, T. (1999) · Science · doi:10.1126/science.284.5415.805 · Cited by 1,629
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Weinberg, E. D. (1978) · Microbiological Reviews · doi:10.1128/mmbr.42.1.45-66.1978 · Cited by 1,254
Protective effects of the sickle cell gene against malaria morbidity and mortality
Aidoo, M., Terlouw, D. J., Kolczak, M. S., McElroy, P. D., ter Kuile, F. O., Kariuki, S., Nahlen, B. L., Lal, A. A., & Udhayakumar, V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08273-9 · Cited by 700
Genetic or Pharmacological Iron Chelation Prevents MPTP-Induced Neurotoxicity In Vivo
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., Viswanath, V., Jacobs, R., Yang, L., Beal, M. F., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00126-0 · Cited by 620
Pardridge, W. M., Boado, R. J., & Farrell, C. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)38267-x · Cited by 606
Rational Design of Sequestering Agents for Plutonium and Other Actinides
Gorden, A. E. V., Xu, J., Raymond, K. N., & Durbin, P. (2003) · Chemical Reviews · doi:10.1021/cr990114x · Cited by 552
Research works printed but not linked: 11
- Pearson, 1963, J. Am. Chem. Soc., 85, 3535
- Thieken, 1992, FEMS Microbiol. Lett., 94, 37, 10.1111/j.1574-6968.1992.tb05285.x · doi:10.1111/j.1574-6968.1992.tb05285.x · Paper page
- Holander, 1988, Can. J. Gastroenterol., 2, 35A
- Hider, 1992, Proc. R. Soc. Edinburgh, 99B, 137
- Hershko, 1978, J. Lab. Clin. Med., 92, 144
- Pippard, 1978, Clin. Sci. Mol. Med., 54, 99
- Wolfe, 1990, Semin. Hematol., 27, 117
- Galanello, 2003, J. Clin. Pharmacol., 43, 565, 10.1177/0091270003253350 · doi:10.1177/0091270003253350 · Paper page
- Piga, 2003, J. Hematol., 88, 489
- Oakley, 1973, JAMA, J. Am. Med. Assoc., 225, 395, 10.1001/jama.1973.03220310031006 · doi:10.1001/jama.1973.03220310031006
- Albert, 1947, Br. J. Exp. Path., 28, 69
Cited by
Nutritional immunity: transition metals at the pathogen–host interface
Hood, M. I., & Skaar, E. P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2836 · Cited by 1,535
Iron homeostasis in host defence and inflammation
Ganz, T., & Nemeth, E. (2015) · Nature Reviews Immunology · doi:10.1038/nri3863 · Cited by 843
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
Jack of all trades: versatile catechol crosslinking mechanisms
Yang, J., Cohen Stuart, M. A., & Kamperman, M. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00185k · Cited by 702
Singh, N., Haldar, S., Tripathi, A. K., Horback, K., Wong, J., Sharma, D., Beserra, A., Suda, S., Anbalagan, C., Dev, S., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4931 · Cited by 208
“Some studies suggest that an iron chelator should have good oral bioavailability and have even smaller size ( < 300Da); however, the main delivery methods with proven effectiveness so far have been through the intra-venous route (483).”
Menyo, M. S., Hawker, C. J., & Waite, J. H. (2013) · Soft Matter · doi:10.1039/c3sm51824h · Cited by 173
Pyridones in drug discovery: Recent advances
Zhang, Y., & Pike, A. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127849 · Cited by 162
Iron-Induced Damage in Cardiomyopathy: Oxidative-Dependent and Independent Mechanisms
Gammella, E., Recalcati, S., Rybińska, I., Buratti, P., & Cairo, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/230182 · Cited by 174
“As a consequence, only with dosages high enough (>10 μM) to reach a 3 : 1 molar ratio of bidentate chelator to iron, stable iron-coordinate complexes and efficient and safe scavenging of excess iron will be achieved [88, 89].”
BackgroundThe “Iron”-y of Iron Overload and Iron Deficiency in Chronic Obstructive Pulmonary Disease
Cloonan, S. M., Mumby, S., Adcock, I. M., Choi, A. M. K., Chung, K. F., & Quinlan, G. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201702-0311pp · Cited by 106
“Intracellular iron chelators such as deferiprone, which specifically target intracellular iron deposits and relocate them outside the cell to prevent cellular iron loading (112, 113), may have more therapeutic efficacy than regular cell-impermeable iron chelators such as deferoxamine (114).”
BackgroundXu, P., Zhang, M., Sheng, R., & Ma, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.12.045 · Cited by 92
Self-citationIron and Copper Intracellular Chelation as an Anticancer Drug Strategy
Gaur, K., Vázquez-Salgado, A. M., Duran-Camacho, G., Dominguez-Martinez, I., Benjamín-Rivera, J. A., Fernández-Vega, L., Carmona‐Sarabia, L., García, A. C., Pérez-Deliz, F., Román, J. A. M., et al. (2018) · Inorganics · doi:10.3390/inorganics6040126 · Cited by 97
“Deferiprone (DFP) (Figure 9) is a bidentate ligand that makes 3:1 ligand:Fe(III) complexes at physiological pH with Fe(III) [161].”
Hydroxypyridinone Journey into Metal Chelation
Cilibrizzi, A., Abbate, V., Chen, Y., Ma, Y., Zhou, T., & Hider, R. C. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00254 · Cited by 92
Self-citationHealy, C., Munoz-Wolf, N., Strydom, J., Faherty, L., Williams, N. C., Kenny, S., Donnelly, S. C., & Cloonan, S. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01722-y · Cited by 78
Bilitewski, U., Blodgett, J. A. V., Duhme‐Klair, A., Dallavalle, S., Laschat, S., Routledge, A., & Schobert, R. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701586 · Cited by 85
The Bacterial Pathogen Xylella fastidiosa Affects the Leaf Ionome of Plant Hosts during Infection
Fuente, L. D. L., Parker, J. K., Oliver, J. E., Granger, S., Brannen, P. M., van Santen, E., & Cobine, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062945 · Cited by 84
“Understanding nutritional immunity in plants could open possibilities for the development of new disease control methods using specific chelators and inhibitors of mineral transport, analogous to the manipulation of metal elements used in animals against bacterial infection [21,22].”
BackgroundIron: Effect of Overload and Deficiency
Hider, R. C., & Kong, X. (2013) · Metal ions in life sciences · doi:10.1007/978-94-007-7500-8_8 · Cited by 91
Self-citationRecent advances in cancer treatment by iron chelators
Corcé, V., Gouin, S. G., Renaud, S., Gaboriau, F., & Deniaud, D. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.094 · Cited by 79
Nagy, T. A., Moreland, S. M., Andrews-Polymenis, H., & Detweiler, C. S. (2013) · Infection and Immunity · doi:10.1128/iai.00412-13 · Cited by 72
“The addition of the iron chelator 2,2=-dipyridyl, which has a similar binding affinity for ferrous and ferric iron (42), prevented the growth of both strains similarly.”
BackgroundCusnir, R., Imberti, C., Hider, R. C., Blower, P. J., & Ma, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010116 · Cited by 70
“Through chemical modification of substituents, Fe3+ affinity, hydrophilicity, metabolic stability and functionality of HPs can be tailored [10].”
BackgroundSelf-citationSingh, Y. P., Pandey, A., Vishwakarma, S., & Modi, G. P. (2018) · Molecular Diversity · doi:10.1007/s11030-018-9878-4 · Cited by 70
Redox-Active Metal Ions and Amyloid-Degrading Enzymes in Alzheimer’s Disease
Kim, N., & Lee, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147697 · Cited by 73
Hydroxamate, a Key Pharmacophore Exhibiting a Wide Range of Biological Activities
Bertrand, S., Hélesbeux, J., Larcher, G., & Duval, O. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575113139990007 · Cited by 74
“Among the natural hydroxamic acid derivatives, deferoxamine B whose mesylate salt is known as Desferal (Figure 1) is an important iron chelator clinically used worldwide to treat iron overload [12].”
BackgroundInfluentialSmoking-induced iron dysregulation in the lung
Zhang, W. Z., Butler, J. J., & Cloonan, S. M. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.07.024 · Cited by 62
Hydroxypyridinone-Based Iron Chelators with Broad-Ranging Biological Activities
Jiang, X., Zhou, T., Bai, R., & Xie, Y. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01480 · Cited by 57
Self-citationInhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
Huff, S. E., Winter, J. M., & Dealwis, C. G. (2022) · Biomolecules · doi:10.3390/biom12060815 · Cited by 70
Polymeric nanocarriers for the treatment of systemic iron overload
Hamilton, J. L., & Kizhakkedathu, J. N. (2015) · Molecular and Cellular Therapies · doi:10.1186/s40591-015-0039-1 · Cited by 53
“The DFO–Fe(III) complex (Figure 4) does not redox-cycle and this reduces the chances of iron redistribution and toxicity within the body [18].”
BackgroundInfluentialWong, B. X., & Duce, J. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00081 · Cited by 49
“Instrumental work carried out on therapeutic design in body’s periphery (Higgs et al., 2012; Zhou et al., 2012) has increasingly been implemented to investigate their value at restoring iron homeostasis within the brain (Zecca et al., 2004; Badrick Jones, 2011; Zorzi et al., 2012).”
BackgroundProchelator BHAPI protects cells against paraquat-induced damage by ROS-triggered iron chelation
Kielar, F., Helsel, M. E., Wang, Q., & Franz, K. J. (2012) · Metallomics · doi:10.1039/c2mt20069d · Cited by 45
Jiang, X., Guo, J., Lv, Y., Yao, C., Zhang, C., Mi, Z., Shi, Y., Gu, J., Zhou, T., Bai, R., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115550 · Cited by 47
Self-citationGutbier, S., Kyriakou, S., Schildknecht, S., Ückert, A., Brüll, M., Lewis, F. W., Dickens, D., Pearson, L. T., Elson, J. L., Michel, S., et al. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02826-y · Cited by 43
Workman, D. G., Tsatsanis, A., Lewis, F. W., Boyle, J. P., Mousadoust, M., Hettiarachchi, N. T., Hunter, M., Peers, C., Tétard, D., & Duce, J. A. (2015) · Metallomics · doi:10.1039/c4mt00326h · Cited by 41
Wijesinghe, T. P., Dharmasivam, M., Dai, C. C., & Richardson, D. R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105889 · Cited by 39
Billings, J. L., Gordon, S. L., Rawling, T., Doble, P., Bush, A. I., Adlard, P. A., Finkelstein, D. I., & Hare, D. J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14676 · Cited by 45
“…the same 1 : 3 stoichiometry (Prachayasittikul et al. 2013) forms even more stable complexes (Fe[II]:8-HQ Kstab = ~10 15; Fe[III]:8-HQ Kstab = ~10 36; Zhou et al. 2012) in a similar manner to deferiprone (Devos et al. 2014), another high affinity Fe chelator (Fe[III]:CQKstab = ~10 35) that is…”
BackgroundQuiles, J. L., Sánchez‐González, C., Ramírez, L. V., Giampieri, F., Navarro‐Hortal, M. D., Xiao, J., Llopis, J., Battino, M. A., & Varela‐López, A. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8051 · Cited by 41
“Some iron chelators have been used to reduce the growth of various tumor types (71, 78, 164).”
Vančo, J., Šindelář, Z., Dvořák, Z., & Trávnı́ček, Z. (2014) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2014.10.002 · Cited by 38
CN128: A New Orally Active Hydroxypyridinone Iron Chelator
Chen, W., Yuan, X. Y., Li, Z., Lu, Z., Kong, S., Jiang, H., Du, H.-B., Pan, X., Nandi, M., Kong, X., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00137 · Cited by 35
Self-citationKaviani, S., Izadyar, M., & Housaindokht, M. R. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2016.12.012 · Cited by 32
“The metal overload disease treatment necessitates the administration of appropriate chelating agents to remove the metals from the body (Zhou et al., 2012; Hider, 2014; Ma et al., 2012).”
BackgroundKhodaverdian, V., Tapadar, S., MacDonald, I. A., Xu, Y., Ho, P.-Y., Bridges, A. E., Rajpurohit, P., Sanghani, B. A., Fan, Y., Thangaraju, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39214-1 · Cited by 35
Anti-inflammatory effects of a novel iron chelator, DIBI, in experimental sepsis
Thorburn, T., Aali, M., Kostek, L., LeTourneau-Paci, C., Colp, P., Zhou, J., Holbein, B. E., Hoskin, D. W., & Lehmann, C. (2017) · Clinical Hemorheology and Microcirculation · doi:10.3233/ch-179205 · Cited by 31
“Unlike classical iron chelators, such as desferrioxamine, representing bacterial derived siderophores to bind iron, hydroxypyridinones can be chemically modified to selectively target iron and conceal it from bacteria, while remaining non-toxic and biocompatible [8, 9].”
Mammalian Target of Rapamycin Complex 1 (mTORC1)-mediated Phosphorylation Stabilizes ISCU Protein
La, P., Yang, G., & Dennery, P. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.424499 · Cited by 30
“Furthermore, iron starvation has been applied in cancer treatment (28).”
BackgroundMathematical calculations of iron complex stoichiometry by direct UV–Vis spectrophotometry
Filipský, T., Říha, M., Hrdina, R., Vávrová, K., & Mladěnka, P. (2013) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2013.06.002 · Cited by 28
Holbein, B. E., Ang, M. T. C., Allan, D. S., Chen, W., & Lehmann, C. (2021) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01242-7 · Cited by 29
Ma, J., Lim, C., Sacher, J. R., Van Houten, B., Qian, W., & Wipf, P. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.06.073 · Cited by 27
Cigarette smoke-induced toxicity consequences of intracellular iron dysregulation and ferroptosis
Sepand, M. R., Maghsoudi, A. S., Shadboorestan, A., Mirnia, K., Aghsami, M., & Raoufi, M. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119799 · Cited by 27
Understanding the Potential and Risk of Bacterial Siderophores in Cancer
Pita-Grisanti, V., Chasser, K. M., Sobol, T., & Cruz‐Monserrate, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.867271 · Cited by 35
“These chelators consist of bidentate, tridentate, and hexadentate ligands that form octahedral complexes with ferric iron (Fe) (24).”
Background89Zr‐ and Fe‐Labeled Polymeric Micelles for Dual Modality PET and T1‐Weighted MR Imaging
Starmans, L. W. E., Hummelink, M. A. P. M., Rossin, R., Kneepkens, E., Lamerichs, R. M. J. N., Donato, K., Nicolay, K., & Grüll, H. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500414 · Cited by 27
Coombs, M. R. P., Grant, T., Greenshields, A. L., Arsenault, D. J., Holbein, B. E., & Hoskin, D. W. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.07.008 · Cited by 25
Hamilton, J. L., Hatef, A., ul‐haq, M. I., Nair, N., Unniappan, S., & Kizhakkedathu, J. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109880 · Cited by 28
Zhang, Q., Jin, B., Wang, X., Lei, S., Shi, Z., Zhao, J. C., Liu, Q., & Peng, R. (2018) · Royal Society Open Science · doi:10.1098/rsos.171492 · Cited by 25
“This extremely strong interaction with tripositive metal cations results from the high electron density of both oxygen atoms [22].”
BackgroundHrubý, M., Santana-Martínez, I., Stephan, H., POUCKOVA, P., Beneš, J., & Štěpánek, P. (2021) · Polymers · doi:10.3390/polym13223969 · Cited by 28
“Due to the redox lability of these complexes, in vivo use is not harmless [18].”
BackgroundA DFT study on the metal ion selectivity of deferiprone complexes
Kaviani, S., Izadyar, M., & Housaindokht, M. R. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107267 · Cited by 24
Kaviani, S., Izadyar, M., Khavani, M., & Housaindokht, M. R. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.113933 · Cited by 24
Hamilton, J. L., ul‐haq, M. I., Creagh, A. L., Haynes, C. A., & Kizhakkedathu, J. N. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600244 · Cited by 24
A boronate prochelator built on a triazole framework for peroxide-triggered tridentate metal binding
Kielar, F., Wang, Q., Boyle, P. D., & Franz, K. J. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.06.011 · Cited by 27
Kaviani, S., & Izadyar, M. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.04.065 · Cited by 20
Design of novel fluorescent mitochondria-targeted peptides with iron-selective sensing activity
Abbate, V., Reelfs, O., Hider, R. C., & Pourzand, C. (2015) · Biochemical Journal · doi:10.1042/bj20150149 · Cited by 21
Self-citationReelfs, O., Abbate, V., Cilibrizzi, A., Pook, M. A., Hider, R. C., & Pourzand, C. (2019) · Metallomics · doi:10.1039/c8mt00257f · Cited by 23
Self-citationSynthesis and iron chelating properties of hydroxypyridinone and hydroxypyranone hexadentate ligands
Zhou, T., Kong, X., & Hider, R. C. (2019) · Dalton Transactions · doi:10.1039/c8dt05014g · Cited by 20
Self-citationZhou, X., Dong, L., & Langtao, S. (2021) · Molecules · doi:10.3390/molecules26226997 · Cited by 19
“Compared with hydroxamate, catechol possesses a relatively higher affinity for ferric io , th ugh the chelation is sensitive to pH value [25].”
BackgroundInfluentialPrediction of Absolute Hydroxyl pKa Values for 3-Hydroxypyridin-4-ones
Chen, Y., Doltsinis, N. L., Hider, R. C., & Barlow, D. J. (2012) · The Journal of Physical Chemistry Letters · doi:10.1021/jz301061m · Cited by 19
Self-citationJakubek, M., Kejík, Z., Kaplánek, R., Antonyová, V., Hromádka, R., Šandriková, V., Sýkora, D., Pavel Martasek, E., & Král, V. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.02.034 · Cited by 19
“It is well known that the iron(II) cation, with a lower charge density, prefers to interact with binding groups containing ‘soft’ donor atoms [16].”
BackgroundRenner, N., Schob, F., Pape, R., Suciu, I., Spreng, A., Ückert, A., Cöllen, E., Bovio, F., Chilian, B., Bauer, J., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103165 · Cited by 19
“Deferoxamine, for instance, reportedly shields all coordination sites of iron, thus preventing hydroxyl radical formation by complexed iron [63].”
BackgroundZhang, Q., Jin, B., Shi, Z., Wang, X., Lei, S., Tang, X., Liang, H., Liu, Q., Gong, M., & Peng, R. (2017) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2017.03.003 · Cited by 18
Degradable poly(catechin) nanoparticles as a versatile therapeutic agent
Sagbas, S., Sahiner, M., Mohapatra, S., Ayyala, R. S., Bhethanabotla, V. R., & Şahiner, N. (2021) · International Journal of Polymeric Materials · doi:10.1080/00914037.2021.1941957 · Cited by 19
Wang, S., Pearson, L. A., Mazmouz, R., Liu, T., & Neilan, B. A. (2022) · Applied and Environmental Microbiology · doi:10.1128/aem.02373-21 · Cited by 17
“ity of pharmaceutically relevant siderophores such as desferrioxamine (21).”
BackgroundChen, Y., Kong, X., Xie, Y., & Hider, R. C. (2017) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2017.12.007 · Cited by 18
Self-citationPrediction of 3-hydroxypyridin-4-one (HPO) log K1 values for Fe(iii)
Chen, Y., Barlow, D. J., Kong, X., Ma, Y., & Hider, R. C. (2012) · Dalton Transactions · doi:10.1039/c2dt31254a · Cited by 16
Self-citationNovel S-Gal® analogs as 1H MRI reporters for in vivo detection of β-galactosidase
Gulaka, P., Yu, J.-X., Liu, L., Mason, R. P., & Kodibagkar, V. D. (2013) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2013.03.001 · Cited by 16
“Catechol moieties exhibit a high affinity for Fe3+ and the complex is expected to stabilize the ferric state preventing other changes under biological conditions [27,28].”
BackgroundCappai, R., Chand, K., Lachowicz, J. I., Chaves, S., Gano, L., Crisponi, G., Nurchi, V. M., Peana, M., Zoroddu, M. A., & Santos, M. A. (2018) · New Journal of Chemistry · doi:10.1039/c8nj00116b · Cited by 16
Wijesinghe, T. P., Kaya, B., Gonzálvez, M. A., Harmer, J. R., Azad, M. G., Bernhardt, P. V., Dharmasivam, M., & Richardson, D. R. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01612 · Cited by 16
Dettweiler, M., Marquez, L., Lin, M., Sweeney-Jones, A. M., Chhetri, B. K., Zurawski, D. V., Kubanek, J., & Quave, C. L. (2020) · Scientific Reports · doi:10.1038/s41598-020-72331-w · Cited by 43
Tuning the Anti(myco)bacterial Activity of 3-Hydroxy-4-pyridinone Chelators through Fluorophores
Rangel, M., Moniz, T., Silva, A. M. N., & Leite, A. (2018) · Pharmaceuticals · doi:10.3390/ph11040110 · Cited by 17
Piperazine derivatives as iron chelators: a potential application in neurobiology
Abdelsayed, S., Duong, N.-T. H., Bureau, C., Michel, P. P., Hirsch, É. C., Chahine, J. E. H., & Serradji, N. (2015) · BioMetals · doi:10.1007/s10534-015-9889-x · Cited by 15
“The affinity of the tricatechol (Table 3) is comparable to that of DFO (Kiss and Farkas 1998; Zhou et al. 2012).”
BackgroundResultInfluentialEfflux systems as a target for anti-biofilm nanoparticles: perspectives on emerging applications
Musioł, R. (2023) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2023.2263910 · Cited by 19
“This effect is more potent in complexes and may be exploited to design novel antibacterial and anticancer drugs [67,68].”
BackgroundMode of iron( iii ) chelation by hexadentate hydroxypyridinones
Zhou, T., Hider, R. C., & Kong, X. (2015) · Chemical Communications · doi:10.1039/c4cc10339d · Cited by 14
Self-citationRashed, R. R., Deghiedy, N. M., El‐Hazek, R. M., El‐Sabbagh, W. A., Rashed, E. R., & El‐Ghazaly, M. A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103913 · Cited by 13
Queirós, C., Leite, A., Couto, M. G. M., Moniz, T., Cunha-Silva, L., Gameiro, P., Silva, A. M. G., & Rangel, M. (2014) · Dyes and Pigments · doi:10.1016/j.dyepig.2014.04.007 · Cited by 14
Article review: Brazilin as potential anticancer agent
Raptania, C. N., Zakia, S., Fahira, A. I., & Amalia, R. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1355533 · Cited by 17
Iron Effects on Clostridioides difficile Toxin Production and Antimicrobial Susceptibilities
Yamaki, J., Chawla, S., Tong, S., Lozada, K. A., & Yang, S. (2022) · Antibiotics · doi:10.3390/antibiotics11050537 · Cited by 14
“Moreover, iron chelation has been shown to reduce iron-induced tissue toxicity and improve patients’ short- and long-term treatment outcomes [49,50].”
BackgroundMoniz, T., Cunha-Silva, L., Mesquita, R. B. R., Miranda, J. L. A., Silva, A. M. N., Silva, A. M. G., Rangel, A. O. S. S., de Castro, B., & Rangel, M. (2018) · Polyhedron · doi:10.1016/j.poly.2018.12.005 · Cited by 13
Li, J., Olaleye, E. D., Kong, X., Zhou, T., Ma, Y., Jurach, J., Rugaie, O. A., Hider, R. C., Zhang, G., Alsam, S., et al. (2016) · Polymer · doi:10.1016/j.polymer.2016.01.073 · Cited by 12
Self-citationSalehi, S., Saljooghi, A. S., & Izadyar, M. (2016) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2016.05.010 · Cited by 10
An overview on ligands of therapeutically interest
Martín, J. (2018) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2018.06.00177 · Cited by 14
Chelating Agents as Tools for the Treatment of Metal Overload
Gumienna‐Kontecka, E., Nurchi, V. M., Szebesczyk, A., Bilska, P., Krzywoszyńska, K., & Kozłowski, H. (2013) · Zeitschrift für anorganische und allgemeine Chemie · doi:10.1002/zaac.201300064 · Cited by 11
Salsbury, L. E., Robertson, K. N., Flewelling, A. J., Li, H., Geier, S. J., Vogels, C. M., Gray, C. A., & Westcott, S. A. (2014) · Canadian Journal of Chemistry · doi:10.1139/cjc-2014-0426 · Cited by 10
Health Benefits of Trace Elements in Human Diseases
Abdel-Aziz, S. M., Abdel-aziz, M. S., & Garg, N. (2016) · Springer eBooks · doi:10.1007/978-3-319-25277-3_7 · Cited by 11
Alizadeh, S. R., Biparva, P., & Ebrahimzadeh, M. A. (2024) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2024.105724 · Cited by 12
Xu, Q., Wang, X., Mu, Z., Zhou, Y., Ding, X., Ji, X., Yan, J., Pan, D., Chen, C., Xu, Y., et al. (2024) · MedComm · doi:10.1002/mco2.473 · Cited by 10
“At 72 h postinjection, the knee joint uptake values of the DFO, DFP, and DFS treatment groups were 7.63 ± 1.34, 24.83 ± 1.23, and 21.83 ± 3.34%ID/g, respectively, which were substantially lower than the value of 50.17 ± 3.15%ID/g in the untreated group.”
BackgroundInfluentialArshad, J. Z., & Hanif, M. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00175f · Cited by 10
Synthesis and Study of Multifunctional Cyclodextrin–Deferasirox Hybrids
Gascon, J. M., Oliveri, V., McGown, A., Kaya, E., Chen, Y., Austin, C., Walker, M., Platt, F. M., Vecchio, G., & Spencer, J. (2019) · ChemMedChem · doi:10.1002/cmdc.201900334 · Cited by 9
Klahn, P., Zscherp, R., & Jimidar, C. C. (2022) · Synthesis · doi:10.1055/a-1783-0751 · Cited by 12
Hashemi, Z., Ebrahimzadeh, M. A., & Biparva, P. (2022) · Journal of Fluorescence · doi:10.1007/s10895-022-02893-7 · Cited by 9
Multicellular aggregation of maltol-modified cells triggered by Fe3+ ions
Ciupa, A., Bank, P. D., & Caggiano, L. (2013) · Chemical Communications · doi:10.1039/c3cc43727b · Cited by 9
Queirós, C., Leite, A., Couto, M. G. M., Cunha-Silva, L., Barone, G., de Castro, B., Rangel, M., Silva, A. M. N., & Silva, A. M. G. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201502093 · Cited by 10
Sridhar, P., Venkatesh, B. C., Kalesha, S., & Sudharani, C. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c8ob00263k · Cited by 8
Özbolat, G., & Yegani, A. A. (2020) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13359 · Cited by 8
Bilitewski, U., Blodgett, J. A. V., Duhme‐Klair, A., Dallavalle, S., Laschat, S., Routledge, A., & Schobert, R. (2017) · Angewandte Chemie · doi:10.1002/ange.201701586 · Cited by 7
The hydrolytic susceptibility of prochelator BSIH in aqueous solutions
Wang, Q., & Franz, K. J. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.019 · Cited by 8
Design and synthesis of 3-isoxazolidone derivatives as new Chlamydia trachomatis inhibitors
Abdelsayed, S., Duong, N.-T. H., Hai, J., Hémadi, M., Chahine, J. E. H., Verbeke, P., & Serradji, N. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.06.056 · Cited by 7
In silico design of mimosine containing peptides as new efficient chelators of aluminum
Mujika, J. I., Torre, G. D., Lachowicz, J. I., & López, X. (2019) · RSC Advances · doi:10.1039/c8ra10139f · Cited by 7
Metadata
- Authors
- Zhou, T., Ma, Y., Kong, X., & Hider, R. C.
- Affiliations
- Zhejiang Gongshang University (CN)
- King's College London (GB)
- Corresponding author
- Hider, Robert C.
- Venue
- Dalton Transactions
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 41
- Issue
- 21
- Pages
- 6371
- ISSN
- 1477-9226 (ISSN-L)
- 1477-9234
- OpenAlex
- W2028066320
- Cited by
- 136
- References
- 142
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 10 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 14 · 2017: 13 · 2016: 7 · 2015: 12 · 2014: 11 · 2013: 15 · 2012: 5
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dalton Transactions (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- iron chelators, chelation therapy, iron overload, beta-thalassaemia major, sickle cell disease, neurodegenerative diseases, microbial infection, drug design, iron toxicity
- MeSH terms
- Anti-Bacterial Agents, Humans, Iron Chelating Agents, Drug Design, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.